Uxi

Endopleura uchi bark is dominated by bergenin, an isocoumarin-class polyphenol C-glycoside of gallic acid that inhibits xanthine oxidase, COX-1/COX-2, and α-glucosidase while activating the DAF-16/FOXO longevity pathway. Preclinical models demonstrate bergenin-driven reductions in polyglutamine aggregate formation and age-related muscle decline in Caenorhabditis elegans, alongside in vitro suppression of inflammatory cyclooxygenases—though no human clinical trials have yet quantified effect sizes in people.

Origin & History

Endopleura uchi is a tree native to the Amazon Basin, distributed across Brazil, Peru, and Colombia, thriving in lowland tropical rainforest ecosystems with high rainfall and rich alluvial soils. The tree produces a yellow-fleshed fruit—called uxi or yellow uxi—prized by Amazonian Indigenous communities, particularly the Kayapó people, for both food and medicine. Bark and fruit are harvested from wild stands, with no significant commercial cultivation documented; bark is sold in regional markets throughout Belém and other Amazonian cities.

Historical & Cultural Context

The Kayapó and other Amazonian Indigenous peoples have used Endopleura uchi for generations as both a staple food source and a medicinal plant, applying bark preparations to treat inflammatory conditions, infections, liver disease, and metabolic complaints such as diabetes and elevated cholesterol. Bark is a recognized commodity in traditional markets of Pará state, Brazil, where it is sold in dried form specifically for its reputed medicinal properties, reflecting deep integration into regional ethnopharmacology. Preparation traditionally involves aqueous decoctions of the bark—boiled and consumed as a tea—while the nutrient-dense fruit pulp is eaten fresh or incorporated into regional sweets and beverages. The plant's Kayapó name and dual identity as both food and medicine exemplifies the concept of 'functional food' long embedded in Amazonian ethnobotanical knowledge systems, predating formal pharmacological investigation by centuries.

Health Benefits

- **Anti-Inflammatory Activity**: Bark and fruit extracts inhibit COX-1 and COX-2 enzymes, reducing prostaglandin synthesis; bergenin is considered the primary driver of this effect based on HPLC-guided fractionation studies.
- **Antioxidant Protection**: High total phenol content—including gallic acid, catechin, and quercetin—correlates strongly with DPPH radical scavenging capacity in fruit pulp extracts, neutralizing reactive oxygen species before cellular damage occurs.
- **Antihyperuricemic Potential**: Extracts inhibit xanthine oxidase (XO), the enzyme responsible for uric acid overproduction, suggesting utility in managing hyperuricemia and gout-related inflammation in a manner analogous to allopurinol, though no clinical dose-response data exist.
- **Antidiabetic Support**: α-Glucosidase inhibition by uxi extracts slows intestinal glucose absorption, potentially blunting postprandial blood glucose spikes; this activity parallels that of pharmaceutical acarbose and warrants formal clinical investigation.
- **Neuroprotective and Anti-Amyloid Effects**: Bergenin activates the DAF-16/FOXO transcription factor pathway in C. elegans, reducing polyQ40 peptide aggregation—a model for amyloid-type protein misfolding—and extending lifespan, suggesting relevance to neurodegenerative disease prevention.
- **Hepatoprotective Effects**: Traditional bark decoctions are used for liver health, and bergenin has demonstrated hepatoprotective properties in related preclinical contexts by reducing oxidative stress and inflammatory cytokine signaling in hepatic tissue.
- **Anti-Cholesterol and Lipid Modulation**: Community use and preliminary in vitro data suggest uxi extracts may support healthy lipid metabolism, potentially through modulation of lipase activity and phenolic-driven antioxidant effects on LDL oxidation.

How It Works

Bergenin, the principal bioactive constituent of Endopleura uchi bark, exerts antioxidant and longevity-associated effects by upregulating the DAF-16/FOXO transcription factor pathway, which governs expression of stress-resistance genes including superoxide dismutases and heat-shock proteins, as demonstrated in C. elegans models. Anti-inflammatory activity is mediated through competitive inhibition of cyclooxygenase enzymes COX-1 and COX-2, reducing arachidonic acid conversion to pro-inflammatory prostaglandins, while xanthine oxidase inhibition curtails superoxide and uric acid co-production. The α-glucosidase inhibitory activity of fruit and bark polyphenols—including gallic acid and catechin—competitively blocks the intestinal brush-border enzyme responsible for disaccharide hydrolysis, delaying glucose absorption and attenuating glycemic excursions. Collectively, bergenin and co-occurring phenolics also chelate transition metals and donate hydrogen atoms to quench free radicals, providing a non-enzymatic antioxidant layer that complements pathway-level regulation.

Scientific Research

The available evidence base for Endopleura uchi consists entirely of in vitro bioassays, phytochemical characterization studies, and invertebrate (C. elegans) in vivo experiments; no human clinical trials have been registered or published as of the available data. Phytochemical analyses using HPLC have reliably identified and quantified bergenin as the dominant bark constituent, providing a reproducible chemical anchor for biological activity studies. In vitro enzyme inhibition assays (XO, COX-1/COX-2, α-glucosidase) and DPPH radical scavenging assays have demonstrated concentration-dependent activity for bark and fruit pulp extracts, but IC50 values have not been systematically translated into human-relevant doses. The C. elegans lifespan and polyQ40 aggregation studies offer mechanistic insight into bergenin's DAF-16/FOXO-dependent neuroprotective potential, though the translational gap to mammalian and human biology remains entirely uncharacterized.

Clinical Summary

No human clinical trials investigating Endopleura uchi bark, fruit, or isolated bergenin for any health outcome have been identified in the available literature. Consequently, no effect sizes, confidence intervals, number-needed-to-treat values, or validated therapeutic endpoints can be reported. Preclinical evidence from cell-free enzyme assays and C. elegans models is consistent with anti-inflammatory, antidiabetic, antihyperuricemic, and neuroprotective biological plausibility, but this evidence tier is classified as preliminary and hypothesis-generating only. Confidence in clinical benefit for humans is currently low, and the ingredient should not be substituted for evidence-based therapies pending properly designed Phase I/II trials.

Nutritional Profile

Fruit pulp moisture ranges from 60.1 to 89.2 g/100 g (fresh weight), with ash content of 1.28–1.32 g/100 g on a dry basis, indicating moderate mineral density. Key minerals in pulp include potassium (260.2–395 mg/100 g), calcium (78.2–87.1 mg/100 g), and notably high aluminum (23.7–28.7 mg/100 g), the last of which is an important safety consideration for chronic consumption. Vitamins A and E are present in the pulp, along with organic acids that contribute to flavor and may enhance polyphenol bioavailability. The bark is particularly concentrated in bergenin (quantified via HPLC as the dominant constituent), while the fruit pulp contains gallic acid, catechin, and quercetin as the predominant phenolics, with total phenol content high enough to produce robust DPPH radical scavenging in vitro; bioavailability of bergenin and fruit polyphenols in humans has not been formally assessed using pharmacokinetic studies.

Preparation & Dosage

- **Traditional Bark Decoction**: Dried stem bark is simmered in water (approximately 10–20 g bark per liter of water) for 20–30 minutes; used by Amazonian communities for inflammation, liver support, and general health—no validated dose has been established.
- **Alcoholic (Ethanolic) Bark Extract**: Used in research settings to isolate bergenin and phenolic fractions; standardized ethanolic extracts are not yet available as commercial supplements.
- **Fresh Fruit Pulp**: Consumed directly or processed into juices and desserts; pulp yield averages 45.66 ± 4.44% (w/w) with moisture content of 60.1–89.2 g/100 g.
- **Aqueous Fruit Pulp Extract**: Used in antioxidant assays; high total phenol content confirmed but no standardized concentration for supplemental use has been defined.
- **Bergenin Standardization**: HPLC quantification of bergenin in bark is methodologically established in research, but no commercial product standardized to a specific bergenin percentage (e.g., 5% or 10%) has been documented.
- **Timing and Dosing Note**: No evidence-based dosing schedule or optimal timing window exists; traditional use is typically as a daily decoction; use caution given high aluminum content in pulp for prolonged consumption.

Synergy & Pairings

Bergenin's DAF-16/FOXO pathway activation may be mechanistically complementary to other FOXO-activating compounds such as resveratrol (which acts via SIRT1-FOXO signaling) and epigallocatechin gallate (EGCG) from green tea, potentially creating additive stress-resistance and neuroprotective effects—though this stack has not been tested in any model system for uxi specifically. The xanthine oxidase inhibitory activity of uxi extracts could synergize with quercetin (also present endogenously in uxi fruit) and tart cherry anthocyanins, which share anti-gout and anti-inflammatory mechanisms, reinforcing uric acid control through complementary enzymatic and scavenging pathways. For antidiabetic applications, combining uxi's α-glucosidase inhibition with berberine's AMPK-activating, glucose-transport-enhancing activity represents a theoretically well-matched pairing, though no co-administration studies exist.

Safety & Interactions

Formal safety studies, including acute or chronic toxicity trials in mammals or humans, have not been published for Endopleura uchi bark or fruit extracts; in vitro and C. elegans data report no overt cytotoxicity, but this does not constitute a human safety profile. The most significant documented safety concern is the high aluminum content of the fruit pulp (23.7–28.7 mg/100 g), which, with chronic high-volume consumption, could contribute to aluminum accumulation—a known neurotoxic risk factor—particularly in individuals with impaired renal function. No specific drug interactions have been characterized, though the enzyme-inhibitory profile of uxi extracts (COX inhibition, xanthine oxidase inhibition, α-glucosidase inhibition) suggests theoretical interactions with NSAIDs, allopurinol, and antidiabetic medications (e.g., acarbose, metformin) that share mechanistic targets. Pregnancy and lactation guidance cannot be provided due to absent safety data; use is not recommended in these populations or in individuals with renal impairment, and maximum safe doses have not been established.